Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
125 hedge funds and large institutions have $1.58B invested in Mirati Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 14 closing their positions.
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
16% more funds holding
Funds holding: 108 → 125 (+17)
1% more capital invested
Capital invested by funds: $1.56B → $1.58B (+$20.2M)
5% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $34.8M
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.8M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$23.6M |
| 3 |
Jennison Associates
New York
|
+$21.4M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$20.2M |
| 5 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$36.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$35.2M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$26.8M |
| 4 |
DM
Deerfield Management
New York
|
-$25.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$8.11M |
MRTX Hedge Fund Activity: Q3 2018 in Review
125 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2018, worth a combined $1.58B — up 1.3% from $1.56B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new MRTX positions and 14 closed out — a net gain of 17 holders — while 49 added to existing stakes and 30 trimmed.
The largest buyer was State Street, adding an estimated $23.8M. The largest seller was Broadfin Capital, cutting an estimated $36.9M.
- 125 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2018, up from 108 in Q2 2018.
- Funds reported $1.58B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2018, up 1.3% quarter-over-quarter.
- 31 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2018 and 14 closed out, a net change of +17 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2018 was State Street, an estimated $23.8M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2018 was Broadfin Capital, an estimated $36.9M sold.
Based on aggregated 13F filings for Q3 2018.